The Deadly Effects of Smoking and Secondhand Smoke

Sep.01.2022
The Deadly Effects of Smoking and Secondhand Smoke
Smoking is a leading cause of death in the US, causing chronic obstructive pulmonary disease, asthma and even diabetes. Secondhand smoke is also harmful.

If you smoke, your body will be harmed - we all know that. But did you know that being around people who smoke today can also harm your body?


Smoking is the leading cause of death in the United States. However, it is often attributed to something else medically speaking. Deaths may be attributed to chronic obstructive pulmonary disease, asthma, and even diabetes - conditions that are worsened by smoking or caused by smoking.


If you don't smoke, you are already doing the first thing you can do to prevent these terrible, but preventable diseases. The second thing you can do is to avoid second-hand smoke," said Todd Mahr, an allergist and immunologist as well as an expert on the harmful effects of smoking at the Gunderson Health System. It means that if you are exposed to second-hand smoke, you are constantly in the presence of people who are smoking.


Second-hand smoke is a bigger problem for young children. When discussing third-hand smoke with parents, they often say "I never smoke around them," but the smoke still lingers on their clothing and in the surrounding area, which can still be harmful, according to Mahr. However, there is now one thing you can do to extend your life expectancy.


He said, "Some people don't consider e-cigarettes as smoking. Being unique is important, but being unique doesn't always mean it's a good thing. People say, 'I'm vaping. All I'm inhaling is water vapor.' But in reality, they contain chemicals that can lead to cancer.


This story is part of a series by the Valley Media Group exploring the leading causes of death from 1999 to 2020. The data in this story is sourced from the Centers for Disease Control and Prevention.


The fourth leading cause of death in the area.


Chronic Lower Respiratory Disease (CLRD) encompasses Chronic Obstructive Pulmonary Disease (COPD), including emphysema and chronic bronchitis, as well as asthma, pulmonary hypertension, and occupational lung diseases.


According to data from the Centers for Disease Control and Prevention, it is the sixth leading cause of death in the United States, responsible for 152,657 deaths.


In the valley region, 4,116 people died from CLRD in 2020, making it the fourth leading cause of death in La Crosse County, Vernon County, Dunn County, Trempealeau County, Chippewa County, and Monroe County in Wisconsin, as well as Houston County and Winona County in Minnesota.


Chronic obstructive pulmonary disease (COPD) accounts for the majority of chronic lower respiratory diseases and is primarily caused by smoking in approximately 85% of cases.


Over time, exposure to irritants in cigarette smoke can weaken the lungs' ability to resist infection, leading to tracheal inflammation and damage to air sacs or alveoli. Long-term exposure to air pollution, smoke, chemicals, or secondhand smoke also contributes to the development of chronic obstructive pulmonary disease (COPD), as does vaping e-cigarettes and smoking marijuana. Symptoms of COPD include shortness of breath, wheezing, or chronic coughing.


Chronic obstructive pulmonary disease (COPD) has decreased from being the fourth leading cause of death in the United States in 2018 to the sixth in 2020, but its incidence rate may be higher than expected.


More than 50% of adults with poor lung function are unaware that they have chronic obstructive pulmonary disease, according to a study conducted in 2013.


Dr. Hafiz Fakih, a pulmonary and critical care specialist at the Greater Los Angeles VA Healthcare System, explains that there may be a potential underreporting of deaths related to chronic obstructive pulmonary disease (COPD) due to the condition being listed as the cause of death instead of the actual underlying cause of death.


Fatal consequences


Smoking is terrible. But just how terrible is it?


Mahr states, "The most important thing is that smoking can lead to everything. We are talking about lower respiratory tract diseases, but it can lead to many illnesses and disabilities, actually harming every organ in the body.


Most Americans are aware that smoking has a significant impact on the lungs, but that's not all. According to Mahr, it affects a person's entire body.


Around 16 million Americans suffer from smoking-related diseases, including lung cancer and chronic obstructive pulmonary disease. However, smoking can also lead to or worsen heart disease, stroke, other lung diseases, diabetes, emphysema, and chronic bronchitis. It even increases the risks of tuberculosis and eye diseases and can severely damage our immune systems. From a medical standpoint, smoking can affect everything. In relation to the COVID-19 virus, smoking also increases the risk of infection.


In recent years, there has been a significant decrease in the smoking rates of adults, going from 20.9% in 2005 to 12.5% in 2020. Additionally, smoking rates among youth have dropped from 23% in 2000 to 2.3% in 2021.


According to Fakih, while the mortality rate for men suffering from chronic obstructive pulmonary disease (COPD) has decreased slightly, "the mortality rate for women with COPD is slightly higher," as the rate of female smokers declining is slower than that of men.


Race is also a factor in smoking rates - 21.9% of American Indians and Alaskan Natives smoke, as do 16.8% of African Americans and Blacks. Non-Hispanic white smokers have a slightly lower smoking rate at 16.6%, but their use of menthol cigarettes is only one-third that of African American smokers. Menthol products make smoking more enjoyable and harder to quit.


According to Fakih, we can manage the damage caused by smoking, but we cannot reverse it. When you quit smoking, the harm will come to an end.


The COVID-19 pandemic has heightened people's awareness of lung diseases. According to Mahr, it is now evident that simply wearing a mask every day is not the straightforward solution for calming lung infections and chronic illnesses.


It all depends on your personal risk factors. Respiratory illnesses are not very common, and most people would attribute them to community-acquired pneumonia and bronchitis. However, they are still fatal. Look at the statistics. Many people are struggling for their lives," Mahr said. "We know that one thing that increases your risk of disease and death is smoking. People should be aware of this. If possible, quit.


Disclaimer: 1. The content of this article is compiled from third-party information and is intended for industry exchange and learning purposes only. 2. The views expressed in this article do not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity and accuracy of the content of the article. The compilation of this article is only for industry exchange and research purposes. 3. Due to limited compiling skills, the compiled article may not fully express the original article, please refer to the original article for accuracy. 4. 2FIRSTS fully supports the Chinese government on any statements and positions related to domestic, Hong Kong, Macau, Taiwan, and foreign affairs. 5. The copyright of the compiled information belongs to the original media and author, and if there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology Dropped From FTSE All-World as International Business Reaches 68.5% of Q2 Revenue
RLX Technology (NYSE: RLX) has been removed from the FTSE All-World Index, effective September 21. FTSE Russell records show RLX was already part of its global equity index universe by 2022, when its American depositary receipts were classified as China Large Cap securities. Trading volume rose to about 44.77 million shares on September 18, roughly 23 times the previous session's volume. RLX reported RMB1.0105 billion in second-quarter revenue, up 14.8% year over year, with international operations contributing 68.5%. The company also acquired a 51% stake in one of Western Europe's largest distributors of next-generation smoke-free and FMCG products in July.
Sep.22
South Korea Constitutional Court Upholds Volume-Based E-Liquid Tax, With Challenged Rates at KRW 370 and KRW 628 per Milliliter
South Korea Constitutional Court Upholds Volume-Based E-Liquid Tax, With Challenged Rates at KRW 370 and KRW 628 per Milliliter
South Korea's Constitutional Court has upheld fixed taxes on nicotine-containing e-cigarette liquids based on solution volume, ruling that challenged provisions imposing KRW 370 per milliliter in individual consumption tax and KRW 628 per milliliter in tobacco consumption tax do not violate the Constitution. The cases stemmed from historical disputes involving importers that reported nicotine as being extracted from tobacco stems rather than leaves. South Korea has since broadened its tobacco definition to include synthetic nicotine, while current tax laws provide reduced rates for certain products not derived from tobacco.
Sep.18
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
Product | BAT Launches VELO WRKS Nicotine Pouches in Sweden, Introducing Dual-Compartment Cans With Two Flavours
Product | BAT Launches VELO WRKS Nicotine Pouches in Sweden, Introducing Dual-Compartment Cans With Two Flavours
British American Tobacco (BAT)'s VELO brand launched the VELO WRKS nicotine pouch range in Sweden on November 2, 2026. The initial release features three Dual Can variants, each containing two separate flavours in a dual-compartment container. Each can holds 20 slim pouches with 8mg of nicotine per pouch and retails for SEK 52.99. According to VELO, the first release, Drop 1, is limited to 75,000 cans and will remain available until February 2027 or while stocks last. VELO positions WRKS as a platform for testing new product concepts and has introduced an online consumer feedback survey. EU trademark records show BAT applied to register VELO WRKS in March 2026 under Class 34, covering nicotine pouches, e-cigarettes, heated tobacco products and other tobacco-related goods.
product
Nov.03
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Product | Four CrossBar 20K 13mL High-Puff Vapes Listed on Pennsylvania's ENDS Directory, Rated for Up to 20,000 Puffs
Four CrossBar 20K disposable e-cigarettes appeared on Pennsylvania's 163-entry ENDS directory ahead of enforcement beginning October 19, 2026. The devices feature 13mL e-liquid reservoirs, 50mg/mL nicotine, 2,000mAh batteries and 0.9Ω mesh coils, with advertised puff counts of up to 20,000. CrossBar was the only modern high-puff disposable series among the directory's 15 disposable entries. Its packaging emphasizes New York design and Japanese-origin flavoring, while historical CrossBar records identify a registered U.S. tobacco manufacturing-related establishment. The link between the newer 13mL devices and earlier 1.3mL PMTA filings remains unconfirmed.
product
Oct.26
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Special Report | Russia Places Four JTI Businesses Under Temporary Management, a First for Tobacco Majors
Russia has placed shares in four Japan Tobacco International businesses under temporary management, the first such move involving a major global tobacco manufacturer, according to Interfax. JTI held 35.8% of Russia's tobacco market by volume in the first nine months of 2026. While British American Tobacco and Imperial Brands have exited Russia, Philip Morris International continues operating there. As the market changes and diplomatic efforts continue, could international tobacco companies that left Russia eventually return?
Nov.06